risk analysis of natalizumab in progressive multifocal leukoencephalopathy
Published 10 years ago • 973 plays • Length 8:18Download video MP4
Download video MP3
Similar videos
-
9:21
what you need to know about natalizumab (tysabri®)
-
5:01
ben turner part 1- nataluzimab (tysabri), pml and jc virus
-
7:31
support you can count on
-
12:11
a reason to fight
-
42:10
dr paul molyneux - managing pml risk in patients treated with natalizumab.
-
7:24
for me, for my family
-
7:40
my treatment, my decision
-
58:44
progressive multifocal leukoencephalopathy
-
35:05
webinar: what is pml?
-
9:30
finding a community within
-
2:14
safely switching from natalizumab to ocrelizumab in patients with ms at risk of pml
-
1:50
a pml risk genetic test to identify at-risk patients on natalizumab
-
13:35
tysabri side effects explained by neurologist
-
6:27
evaluating natalizumab’s risk-benefit profile in ms
-
37:00
professor david clifford - 'pml and multiple sclerosis'
-
8:12
answering viewers questions: tysabri (natalizumab) and jc virus
-
7:03
ms and tysabri related pml: the real facts
-
5:42
risk of progressive multifocal leukoencephalopathy in oral therapies for multiple sclerosis
-
9:30
discussing jc virus status